AbCellera Biologics Inc.

Item 7.01 Regulation FD On August 10, 2026, AbCellera Biologics Inc. (the “Company”) issued a press release announcing positive top-line results from the Phase 2 portion of its Phase 1/2 clinical trial evaluating ABCL635, an investigational neurokinin 3 receptor (NK3R) antagonist antibody, which is furnished as Exhibit 99.1 to this Current Report on Form 8-K. In connection with announcing the top-line results from the Phase 2 portion of its Phase 1/2 clinical trial evaluating ABCL635, the Company will hold an investor conference call and webcast at 4:30 a.m. Pacific Time (7:30 a.m. Eastern Time) today. The webcast and accompanying investor presentation will be accessible on the “Investors” section of the company website at www.abcellera.com. A copy of the investor presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K. The information in Item 7.01 of this Form 8-K (including the exhibits attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall such information be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise stated in such filing.